These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21288101)

  • 21. Establishment of a CYP2C19 genotyping assay for clinical use.
    Cervinski MA; Schwab MC; Lefferts JA; Lewis LD; Lebel KA; Tyropolis AM; Pflueger SM; Tsongalis GJ
    Am J Clin Pathol; 2013 Feb; 139(2):202-7. PubMed ID: 23355205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.
    Beitelshees AL; Horenstein RB; Vesely MR; Mehra MR; Shuldiner AR
    Clin Pharmacol Ther; 2011 Mar; 89(3):455-9. PubMed ID: 21270785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
    Namazi S; Kojuri J; Khalili A; Azarpira N
    Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Taubert D; Bouman HJ; van Werkum JW
    N Engl J Med; 2009 May; 360(21):2249-50; author reply 2251. PubMed ID: 19458375
    [No Abstract]   [Full Text] [Related]  

  • 25. The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel.
    Tousoulis D; Siasos G; Zaromitidou M; Oikonomou E; Maniatis K; Kioufis S; Kokkou E; Papavassiliou AG; Stefanadis C
    Int J Cardiol; 2013 Sep; 168(2):1594-6. PubMed ID: 23402725
    [No Abstract]   [Full Text] [Related]  

  • 26. Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines.
    Steinhubl SR
    Circulation; 2010 Feb; 121(4):481-3. PubMed ID: 20083686
    [No Abstract]   [Full Text] [Related]  

  • 27. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
    Farid NA; Kurihara A; Wrighton SA
    J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clopidogrel resistance - a clear problem with an unclear solution.
    Bansilal S; Bhatt DL
    Indian Heart J; 2012; 64(4):353-5. PubMed ID: 22929816
    [No Abstract]   [Full Text] [Related]  

  • 30. Clopidogrel and CYP2C19 testing: ready for clinical prime time?
    Hulot JS; Hajjar R; Montalescot G
    Clin Chem; 2012 Jan; 58(1):154-7. PubMed ID: 21940658
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pharmacogenetics of clopidogrel and its clinical significance].
    Panchenko EP; Komarov AL
    Kardiologiia; 2012; 52(9):44-52. PubMed ID: 23098546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
    Miao J; Liu R; Li Z
    Lancet; 2009 Apr; 373(9670):1171-2; author reply 1172-3. PubMed ID: 19345824
    [No Abstract]   [Full Text] [Related]  

  • 33. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical assessment, platelet reactivity measurement or genetic testing after acute coronary syndrome? What benefits the patient?
    Keßler M; Rottbauer W; Koenig W
    EuroIntervention; 2013 Jul; 9(3):299-301. PubMed ID: 23872645
    [No Abstract]   [Full Text] [Related]  

  • 35. Personalised antiplatelet therapy: are we ready for prime time? Data from China.
    Li J; Huo Y
    EuroIntervention; 2013 Jul; 9(3):296-8. PubMed ID: 23872644
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clopidogrel resistance--risk factor in patients with acute coronary syndromes].
    Costache Il; Rusu C; Ivanov I; Popescu R; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):383-8. PubMed ID: 23077924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic determinants of response to clopidogrel and cardiovascular events.
    Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L;
    N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic variability in response to clopidogrel therapy: clinical implications.
    Huber K
    Eur Heart J; 2010 Dec; 31(24):2974-6. PubMed ID: 20846994
    [No Abstract]   [Full Text] [Related]  

  • 39. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
    Bhattacharyya S; Rakhit R
    Lancet; 2009 Apr; 373(9670):1171; author reply 1172-3. PubMed ID: 19345825
    [No Abstract]   [Full Text] [Related]  

  • 40. Putting genomics into practice.
    Holmes MV; Casas JP; Hingorani AD
    BMJ; 2011 Aug; 343():d4953. PubMed ID: 21816737
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.